Overview

HAL-MPE1 Safety and Tolerability Study

Status:
Completed
Trial end date:
2019-09-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to confirm safety and tolerability of incremental doses of HAL-MPE1 subcutaneous immunotherapy (SCIT) in peanut allergic adults, and subsequently assess the safety and tolerability in adolescents and children with peanut allergy.
Phase:
Phase 1
Details
Lead Sponsor:
HAL Allergy